https://www.selleckchem.com/products/ml385.html
Introduction Recently, the generic formulation of FP/SAL FDC has been approved in COPD. Although FP/SAL FDC has been the first long acting FDC approved in COPD, no systematic review assessed the effect of this combination for the treatment of COPD by considering specifically Phase IV studies. The aim of this review was to systematically assess the effect of FP/SAL FDC in COPD patients enrolled in Phase IV studies.Areas covered The question of this systematic review was to examine the evidence regarding the impact of FP/SAL FDC for the tre
Like
Comment
Share
